6tpe: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
 
Line 3: Line 3:
<StructureSection load='6tpe' size='340' side='right'caption='[[6tpe]], [[Resolution|resolution]] 2.87&Aring;' scene=''>
<StructureSection load='6tpe' size='340' side='right'caption='[[6tpe]], [[Resolution|resolution]] 2.87&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[6tpe]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TPE OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6TPE FirstGlance]. <br>
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TPE OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6TPE FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NTW:2-[4-(3-methyl-6-oxidanylidene-1,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexyl]ethanenitrile'>NTW</scene></td></tr>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.87&#8491;</td></tr>
<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=PTR:O-PHOSPHOTYROSINE'>PTR</scene></td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NTW:2-[4-(3-methyl-6-oxidanylidene-1,7-dihydropyrazolo[3,4-b]pyridin-4-yl)cyclohexyl]ethanenitrile'>NTW</scene>, <scene name='pdbligand=PTR:O-PHOSPHOTYROSINE'>PTR</scene></td></tr>
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">JAK1, JAK1A, JAK1B ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6tpe FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tpe OCA], [https://pdbe.org/6tpe PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6tpe RCSB], [https://www.ebi.ac.uk/pdbsum/6tpe PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6tpe ProSAT]</span></td></tr>
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Non-specific_protein-tyrosine_kinase Non-specific protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.2 2.7.10.2] </span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6tpe FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tpe OCA], [http://pdbe.org/6tpe PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6tpe RCSB], [http://www.ebi.ac.uk/pdbsum/6tpe PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6tpe ProSAT]</span></td></tr>
</table>
</table>
== Function ==
[[http://www.uniprot.org/uniprot/JAK1_HUMAN JAK1_HUMAN]] Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway. Kinase partner for the interleukin (IL)-2 receptor.
<div style="background-color:#fffaf0;">
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
== Publication Abstract from PubMed ==
Line 21: Line 17:
</div>
</div>
<div class="pdbe-citations 6tpe" style="background-color:#fffaf0;"></div>
<div class="pdbe-citations 6tpe" style="background-color:#fffaf0;"></div>
==See Also==
*[[Janus kinase 3D structures|Janus kinase 3D structures]]
== References ==
== References ==
<references/>
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
[[Category: Human]]
[[Category: Large Structures]]
[[Category: Large Structures]]
[[Category: Non-specific protein-tyrosine kinase]]
[[Category: Burhardt MN]]
[[Category: Burhardt, M N]]
[[Category: Carnerup MA]]
[[Category: Carnerup, M A]]
[[Category: Hansen BB]]
[[Category: Hansen, B B]]
[[Category: Jepsen TH]]
[[Category: Jepsen, T H]]
[[Category: Jerre A]]
[[Category: Jerre, A]]
[[Category: Jestel A]]
[[Category: Jestel, A]]
[[Category: Lammens A]]
[[Category: Lammens, A]]
[[Category: Larsen J]]
[[Category: Larsen, J]]
[[Category: Larsen M]]
[[Category: Larsen, M]]
[[Category: Molck C]]
[[Category: Molck, C]]
[[Category: Nasipireddy VR]]
[[Category: Nasipireddy, V R]]
[[Category: Rai S]]
[[Category: Rai, S]]
[[Category: Ritzen A]]
[[Category: Ritzen, A]]
[[Category: Seitzberg JG]]
[[Category: Seitzberg, J G]]
[[Category: Sindet R]]
[[Category: Sindet, R]]
[[Category: Vifian T]]
[[Category: Vifian, T]]
[[Category: Complex]]
[[Category: Inhibitor]]
[[Category: Janus kinase]]
[[Category: Proteros biostructures gmbh]]
[[Category: Transferase]]

Latest revision as of 16:09, 6 November 2024

Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivityFragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity

Structural highlights

Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:X-ray diffraction, Resolution 2.87Å
Ligands:,
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Publication Abstract from PubMed

Herein, we report the discovery of a series of JAK1-selective kinase inhibitors with high potency and excellent JAK family subtype selectivity. A fragment screening hit 1 with a pyrazolopyridone core and a JAK1 bias was selected as the starting point for our fragment-based lead generation efforts. A two-stage strategy was chosen with the dual aims of improving potency and JAK1 selectivity: Optimization of the lipophilic ribose pocket-targeting substituent was followed by the introduction of a variety of P-loop-targeting functional groups. Combining the best moieties from both stages of the optimization afforded compound 40, which showed excellent potency and selectivity. Metabolism studies in vitro and in vivo together with an in vitro safety evaluation suggest that 40 may be a viable lead compound for the development of highly subtype-selective JAK1 inhibitors.

Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity.,Hansen BB, Jepsen TH, Larsen M, Sindet R, Vifian T, Burhardt MN, Larsen J, Seitzberg JG, Carnerup MA, Jerre A, Molck C, Lovato P, Rai S, Nasipireddy VR, Ritzen A J Med Chem. 2020 Jun 8. doi: 10.1021/acs.jmedchem.0c00359. PMID:32462873[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

See Also

References

  1. Hansen BB, Jepsen TH, Larsen M, Sindet R, Vifian T, Burhardt MN, Larsen J, Seitzberg JG, Carnerup MA, Jerre A, Molck C, Lovato P, Rai S, Nasipireddy VR, Ritzen A. Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity. J Med Chem. 2020 Jun 8. doi: 10.1021/acs.jmedchem.0c00359. PMID:32462873 doi:http://dx.doi.org/10.1021/acs.jmedchem.0c00359

6tpe, resolution 2.87Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA